有前景的抗丙型肝炎病毒药物靶标。
Promising targets for anti-hepatitis C virus agents.
机构信息
Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan.
出版信息
Curr Med Chem. 2011;18(8):1239-44. doi: 10.2174/092986711795029672.
Hepatitis C virus (HCV) infection is a serious global health problem, with 3-4 million new cases reported each year. Chronic HCV infection places 170 million people at risk of developing liver cirrhosis and hepatocellular carcinoma. However, difficulties in preparing HCV particles in vitro have delayed development of effective anti-HCV therapies. In 2005, Wakita et al. developed an in vitro method to prepare HCV particles, thereby enabling researchers to better understand the mechanism of HCV infection. Other recent advances include development of a virus-free system for evaluating HCV replication and the identification of HCV receptors, such as claudin-1 and occludin, that may serve as targets for anti-HCV drugs. In this review, we discuss recent findings in HCV infection research, including discovery of new potential targets for anti-HCV therapy.
丙型肝炎病毒（HCV）感染是一个严重的全球健康问题，每年报告的新发病例有 300 万至 400 万例。慢性 HCV 感染使 1.7 亿人面临发展为肝硬化和肝细胞癌的风险。然而，由于难以在体外制备 HCV 颗粒，抗 HCV 治疗的研发进展缓慢。2005 年，Wakita 等人开发了一种体外制备 HCV 颗粒的方法，从而使研究人员能够更好地了解 HCV 感染的机制。其他最近的进展包括开发用于评估 HCV 复制的无病毒系统，以及鉴定 HCV 受体，如 Claudin-1 和 Occludin，它们可能成为抗 HCV 药物的靶点。在这篇综述中，我们讨论了 HCV 感染研究的最新发现，包括发现新的抗 HCV 治疗潜在靶点。
Zotero 插件